Jon R. Levine - 27 Oct 2023 Form 4 Insider Report for MARIMED INC. (MRMD)

Role: President and CEO, Director, 10%+ Owner
Signature: /s/ Jon R. Levine
Issuer symbol: MRMD
Transactions as of: 27 Oct 2023
Net transactions value: -$13,350
Form type: 4
Filing time: 30 Oct 2023, 17:24:42 UTC
Previous filing: 01 May 2023
Next filing: 09 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRMD	Common stock	Options Exercise		+138,889	+0.69%		20,240,472	27 Oct 2023	Direct	F1
transaction	MRMD	Common stock	Sale	$13,350	-41,590	-0.21%	$0.3210	20,198,882	27 Oct 2023	Direct	F2
holding	MRMD	Common stock						6,684,640	27 Oct 2023	By the Jon Levine Family Trust	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRMD	Restricted Stock Units (RSU)	Options Exercise	$0	-138,889	-20%	$0.000000	555,555	27 Oct 2023	Common Stock, par value $.001 per share	138,889		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	RSUs convert to shares of common stock on a one-for-one basis.
F2	Reflects shares of common stock sold pursuant to a Rule 10b5-1 instruction letter previously adopted by the Reporting Person prior to February 27, 2023 to satisfy tax withholding obligations in connection with the vesting of RSUs.
F3	These shares are held in trust for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4	The RSUs vest over a three year period in equal one-sixth installments every six months following the October 27, 2022 grant date, in accordance with the terms of an award agreement, between the Issuer and the Reporting Person.